GUILFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the appointment of Jay S. Fine, Ph.D. to its Board of Directors. Dr. Fine has a strong track record of drug discovery and development leadership in respiratory diseases, oncology, immunology and fibrotic disease indications.

康涅狄格州吉尔福德，2024年1月24日（环球通讯社）--OrphAI Therapeutics Inc.（“OrphAI”）是一家临床阶段的生物制药公司，开发针对罕见疾病的新型疗法，今天宣布任命Jay S.Fine博士为董事会成员。Fine博士在呼吸系统疾病、肿瘤学、免疫学和纤维化疾病适应症方面拥有强大的药物发现和开发领导记录。

His leadership has contributed to the progression of over 30 new molecular entities into clinical development, leading to the commercial launch of multiple products including Skyrizi™ for Plaque Psoriasis, Psoriatic Arthritis and Crohn’s Disease and Spevigo™ for Generalized Pustular Psoriasis. He has chaired various governance and steering committees at several global pharmaceutical companies.

他的领导为30多个新分子实体进入临床开发做出了贡献，导致包括Skyrizi在内的多种产品的商业推出™用于斑块状牛皮癣，牛皮癣关节炎，克罗恩病和斯佩维戈™用于全身脓疱性牛皮癣。他曾担任多家全球制药公司的各种治理和指导委员会的主席。

Dr. Fine currently serves as President of Research and Development at EvolveImmune Therapeutics, a development-stage company focused on advancing differentiated immunotherapeutic approaches for the treatment of cancer. Previously, he served as Senior Vice President and Global Therapeutic Area Head for Immunology and Respiratory Diseases Research at Boehringer Ingelheim and as the Discovery Research Site Head at their Ridgefield, CT location.

Fine博士目前担任EvolveImmune Therapeutics的研发总裁，EvolveImmune Therapeutics是一家处于发展阶段的公司，专注于推进用于治疗癌症的差异化免疫治疗方法。此前，他曾担任勃林格殷格翰免疫学和呼吸系统疾病研究高级副总裁兼全球治疗领域负责人，并在其位于康涅狄格州里奇菲尔德的发现研究网站担任负责人。

Dr. Fine also served as Head of Translational Biology at Roche Pharmaceuticals, was a Director in the Inflammation department at Schering-Plough and worked in the Biologic Response Modifiers Program at the National Cancer Institute. He holds a B.S. degree from Cornell University and a Ph.D. from the University of Rochester School of Medicine.

Fine博士还曾担任罗氏制药公司的转化生物学负责人，先灵葆雅公司炎症科主任，并在美国国家癌症研究所的生物反应调节剂项目中工作。他拥有康奈尔大学的学士学位和罗切斯特大学医学院的博士学位。

Dr. Fine has authored over 75 scientific publications and patents and has been the recipient of numerous honors and awards during his career. “Jay Fine represents an extraordinary resource .

Fine博士撰写了75多篇科学出版物和专利，并在其职业生涯中获得了众多荣誉和奖项。“Jay Fine代表了一种非凡的资源。